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Abstract
Background: Prevalence of allergic diseases in infants, whose parents and siblings do not have allergy, is
approximately 10% and reaches 20–30% in those with an allergic first-degree relative. Intestinal microbiota may
modulate immunologic and inflammatory systemic responses and, thus, influence development of sensitization and
allergy. Probiotics have been reported to modulate immune responses and their supplementation has been
proposed as a preventive intervention.
Objective: The World Allergy Organization (WAO) convened a guideline panel to develop evidence-based
recommendations about the use of probiotics in the prevention of allergy.
Methods: We identified the most relevant clinical questions and performed a systematic review of randomized
controlled trials of probiotics for the prevention of allergy. We followed the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) approach to develop recommendations. We searched for and
reviewed the evidence about health effects, patient values and preferences, and resource use (up to November
2014). We followed the GRADE evidence-to-decision framework to develop recommendations.
Results: Currently available evidence does not indicate that probiotic supplementation reduces the risk of
developing allergy in children. However, considering all critical outcomes in this context, the WAO guideline panel
determined that there is a likely net benefit from using probiotics resulting primarily from prevention of eczema.
The WAO guideline panel suggests: a) using probiotics in pregnant women at high risk for having an allergic child;
b) using probiotics in women who breastfeed infants at high risk of developing allergy; and c) using probiotics in
infants at high risk of developing allergy. All recommendations are conditional and supported by very low
quality evidence.
Conclusions: WAO recommendations about probiotic supplementation for prevention of allergy are intended to
support parents, clinicians and other health care professionals in their decisions whether to use probiotics in pregnancy
and during breastfeeding, and whether to give them to infants.
Keywords: Allergy, Prevention, Probiotics, Practice guidelines, GRADE
* Correspondence: brozekj@mcmaster.ca
†Equal contributors
3Department of Clinical Epidemiology and Biostatistics, McMaster University
Health Sciences Centre, Room 2C19, 1200 Main Street West, Hamilton, ON
L8N 3Z5, Canada
21Department of Medicine, McMaster University, Hamilton, ON, Canada
Full list of author information is available at the end of the article
journal
© 2015 Fiocchi et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Fiocchi et al. World Allergy Organization Journal  (2015) 8:4 
DOI 10.1186/s40413-015-0055-2
Executive summary
The purpose of this document is to provide evidence-
based recommendations about the use of probiotic sup-
plements for the primary prevention of allergies.
Prevalence of allergic diseases in infants is approxi-
mately 10% in those without an allergic parent or sibling
and 20% to 30% in those with allergy in their relatives.
Studies suggest that intestinal microbiota may modulate
immunologic and inflammatory systemic responses and,
thus, influence development of sensitization and allergy.
Probiotics are living microorganisms that when adminis-
tered to humans in adequate doses may confer a health
benefit. They have been proposed to modulate immune
responses and have been advocated as therapeutic and
preventive interventions for allergic diseases.
Methodology
The methods used to develop clinical recommendations
in this document follow the Grading of Recommenda-
tions, Assessment, Development and Evaluation (GRADE)
approach. The Guideline panel included clinicians and re-
searchers in the field of allergy (allergists), pediatricians,
primary care physicians, and methodologists. Potential
conflicts of interests were managed as suggested by the
World Health Organization.
The guideline panel developed and graded the recom-
mendations and assessed the quality of the supporting
evidence following the GRADE approach. The quality of
evidence (also called confidence in the available estimates
of health effects or certainty in the evidence) is categorized
as: high, moderate, low or very low based on consideration
of risk of bias, directness of evidence, consistency and pre-
cision of the estimates. Low and very low quality evidence
indicates that the estimated effects of interventions are
very uncertain and further research is very likely to influ-
ence resulting recommendations.
Interpretation of strong and conditional
recommendations
The strength of recommendations is expressed as either
strong (guideline panel recommends…) or conditional
(guideline panel suggests…) Understanding the interpret-
ation of these two grades of strength of recommendations
is essential for judicious health care decision-making and
has explicit implications as follows:
Strong recommendation
◾ For patients: most individuals in this situation would
want the recommended course of action, and only a
small proportion would not.
◾ For clinicians: most individuals should receive the
intervention. Adherence to this recommendation
according to the guideline could be used as a quality
criterion or performance indicator. Formal decision
aids are not likely to be needed to help individuals
make decisions consistent with their values and
preferences.
◾ For policy makers: the recommendation can be
adopted as policy in most situations.
Conditional recommendation
◾ For patients: the majority of individuals in this
situation would want the suggested course of action,
but many would not.
◾ For clinicians: recognize that different choices will be
appropriate for individual patients and that you must help
each patient arrive at a management decision consistent
with his or her values and preferences. Decision aids may
be useful in helping individuals to make decisions
consistent with their values and preferences.
◾ For policy makers: policy-making will require
substantial debate and involvement of various
stakeholders.
How to use these guidelines
The GLAD-P guidelines about the use of probiotics pro-
vide the basis for rational, informed decisions for clinicians,
parents and other decision makers. Clinicians, patients,
third-party payers, institutional review committees, other
stakeholders, or the courts should never view these recom-
mendations as dictates. No recommendation can take into
account all of the often-compelling unique individual cir-
cumstances but provides guidance. However, no one
charged with evaluating health care professional’s actions
should attempt to apply the recommendations from these
guidelines by rote or in a blanket fashion.
Recommendations
Note: statements about the underlying values and prefer-
ences as well as qualifying remarks accompanying each
recommendation are its integral parts and serve to facili-
tate more accurate interpretation; they should never be
omitted when quoting or translating recommendations
from these guidelines.
Recommendation 1
The WAO guideline panel suggests using probiotics in
pregnant women at high risk for allergy in their children,
because considering all critical outcomes, there is a net
benefit resulting primarily from prevention of eczema (con-
ditional recommendation, very low quality evidence).
Values and preferences
This recommendation places a relatively high value on
prevention of eczema in children, and a relatively lower
value on avoiding possible adverse effects.
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Explanations and other considerations
There is lack of evidence that probiotics prevent any other
allergy. In most studies probiotics were used in the last 3
months of pregnancy. This recommendation applies to
otherwise healthy women and cannot be generalized to
those with compromised immune system function. High
risk for allergy in a child is defined as biological parent or
sibling with existing or history of allergic rhinitis, asthma,
eczema, or food allergy.
Recommendation 2
The WAO guideline panel suggests using probiotics in
women who breastfeed infants at high risk of developing al-
lergy, because considering all critical outcomes, there is a
net benefit resulting primarily from prevention of eczema
(conditional recommendation, very low quality evidence).
Values and preferences
This recommendation places a relatively high value on
prevention of development of eczema, and relatively
lower value on avoiding possible adverse effects.
Explanations and other considerations
There is lack of evidence that probiotics prevent any
other allergy. This recommendation applies to otherwise
healthy women and cannot be generalized to those with
compromised immune system function. High risk for al-
lergy in a child is defined as biological parent or sibling
with existing or history of allergic rhinitis, asthma, ec-
zema, or food allergy.
Recommendation 3
The WAO guideline panel suggests using probiotics in in-
fants at high risk of developing allergies, because consider-
ing all critical outcomes, there is a net benefit resulting
primarily from prevention of eczema (conditional recom-
mendation, very low quality evidence).
Values and preferences
This recommendation places a relatively high value on
prevention of eczema, and relatively lower value on
avoiding possible adverse effects.
Explanations and other considerations
There is lack of evidence that probiotics prevent any
other allergy. This recommendation applies to otherwise
healthy infants with the goal of preventing allergies. It
does not apply to the use of probiotics for other indica-
tions, e.g. prevention of antibiotic-associated diarrhea or
enterocolitis in premature infants.
Scope and purpose
The purpose of this document is to evaluate the current
evidence and provide guidance on the use of probiotics
for the primary prevention of allergies. The target audience
of these guidelines are general practitioners, pediatricians,
specialists in allergic disease and immunology, respiratory
medicine and dermatologists managing adults and children
with any kind of allergy. General internists, and other
health care professionals and policy makers involved in
may also benefit from these guidelines. Policy makers inter-
ested in these guidelines include those involved in develop-
ing local, national or international plans with the goal to
reduce incidence of allergy and resource direct and indirect
costs related to allergic diseases [1]. This document may
also serve as the basis for development and implementa-
tion of locally adapted guidelines.
Introduction
Allergic diseases represent a spectrum of health condi-
tions and a worldwide burden in different populations
[2]. In infants, its prevalence depends highly on the aller-
gic status of their parents, being approximately of 10%
in those without an allergic parent or sibling, versus 20%
to 30% in those with an atopic background in their first
degree relatives [3].
In recent years, more attention has been given to the
intestinal microbiota and its influence on sensitization
and the origins of allergic disease, as it may modulate
immunologic and inflammatory systemic responses [4].
The intestinal microbiota hypothesis has been proposed
to explain the rising incidence of allergic disorders [5].
Probiotics are living microorganisms that when adminis-
tered to humans in certain doses may confer a health
benefit. They have been proposed as immune-modulators
of the allergic response by affecting phagocytosis and pro-
duction of pro-inflammatory cytokines, and thus are being
advocated as therapeutic and preventive interventions for
allergic diseases [6,7].
The Guidelines for Atopic Disease Prevention (GLAD-P)
is a joint effort of the World Allergy Organization
(WAO) and the Department of Clinical Epidemiology &
Biostatistics at McMaster University to evaluate the
current evidence on the preventive effect of probiotics,
prebiotics, and vitamin D on allergic diseases and related
clinically important outcomes. This document provides
recommendations and the rationale for use of probiotics.
For clarity of communication we used the following
definitions throughout the document:
• Probiotics: "live microorganisms which, when
administered in adequate amounts as part of food, confer
a health benefit on the host” [8] Probiotics are present in
everyday food (e.g. yoghurt or fermented milk) and they
are a common exposure in almost everyone's life. For the
purpose of this document we considered probiotics as a
supplementary therapeutic agent used for the prevention
of allergy; we have not considered what everyday general
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food people should consume. Of note, even though many
species of microorganisms (e.g. Lactobacilli and
Bifidobacteria) have been studied and the probiotic
characteristics were confirmed for many of their strains,
not all strains are probiotics.
• High risk for allergy in a child: biological parent or
sibling with existing or history of allergic rhinitis,
asthma, eczema, or food allergy [9].
• Weaning or complementary feeding: the period
during which any other foods or liquids are provided
along with breast milk or infant formula [10].
Methods
Panel composition and meetings
We followed the procedures and methodology using the
guideline development checklist (GDC) [11] and the
guideline development tool (GDT) [12] to assemble team
of experts including allergists, pediatricians, family physi-
cians and representatives of the general public.
The guideline panel included methodologist who helped
preparing systematic reviews and evidence summaries
following the GRADE (Grading of Recommendations,
Assessment, Development and Evaluation) approach.
A face-to-face meeting was held in December 2013 co-
inciding with the WAO Symposium on Immunotherapy
and Biologics in Chicago, Illinois. During the meeting the
guideline panel discussed specific questions, the existing
research evidence and made recommendations.
Disclosure of potential conflicts of interest
Guideline panel members disclosed all potential conflicts
of interest according to the World Health Organization
policies. The chairs (AF, RP and HJS) reviewed and re-
solved all potential conflicts of interest of panel members
(see Additional file 1 for the list of declared conflicts of
interest for all panel members). During all deliberations,
panel members with potential conflicts of interest
abstained from decisions about specific questions being
asked and recommendations related to their potential
conflict of interest.
The WAO provided meeting facilities during its Sym-
posium and financial support to perform systematic re-
views to support recommendations. The views and
interests of the WAO as well as of any commercial en-
tity that provided external funding for WAO had no in-
fluence on the final recommendations.
Formulating specific clinical questions and determining
outcomes of interest
We used the electronic tools Guideline Development
Tool (www.guidelinedevelopment.org) [12] and Survey-
Monkey (www.surveymonkey.com) to brainstorm and
subsequently prioritize questions related to the use of
probiotics for the prevention of allergy.
The following questions were prioritized and addressed
in this document:
1. Should probiotics versus no probiotics be used in
pregnant women?
We intended to examine the effects in subpopulations
of children at high and average risks for allergies (see
definitions above).
2. Should probiotics versus no probiotics be used in
breastfeeding women?
We intended to examine the effects in subpopulations
of children at high and average risks for allergies (see
definitions above).
3. Should probiotics versus no probiotics be used in
infants?
We intended to examine the effects in subpopulations
of children at high and average risks for allergies (see defi-
nitions above), exclusively and non-exclusively breastfed
infants, and infants being weaned.
The guideline selected outcomes of interest for each
question following the approach suggested by the GRADE
Working Group [13]. All outcomes were identified a priori
and the panel explicitly rated their relative importance for
decision-making. Ranking outcomes by their relative im-
portance can help to focus attention on those outcomes
that are considered most important and help to resolve or
clarify potential disagreements.
Evidence review and development of clinical
recommendations
Evidence summaries for each question were prepared by
the methodologists (JB, CCG, JJYN and HJS) following
the GRADE approach and using the Guideline Develop-
ment Tool (www.guidelinedevelopment.org). All guide-
line panel members reviewed the summaries of evidence
and made corrections when appropriate. We based the
evidence summaries on a systematic review of the
literature performed specifically for these guidelines
(Cuello-Garcia et al. in preparation). We followed the
methods of the Cochrane Collaboration (handbook.
cochrane.org) and assessed the risk of bias at the
outcome level using the Cochrane Collaboration’s risk of
bias tool [14]. Subsequently, we assessed the quality of
the body of evidence (i.e. confidence in the estimated ef-
fects) for each of the outcomes of interest following the
GRADE approach based on the following criteria: risk of
bias, precision, consistency and magnitude of the esti-
mates of effects, directness of the evidence, risk of publi-
cations bias, presence of dose–effect relationship, and an
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assessment of the effect of residual, opposing confound-
ing. Quality was categorized into 4 levels ranging from
very low to high quality. In addition, we searched for
evidence about values and preferences and cost of pro-
biotic supplementation. We prepared the evidence-to-
decision tables based on the estimates of the health ef-
fects, values and preferences and resource use.
During the meeting the guideline panel developed rec-
ommendations based on the evidence summaries and
the evidence-to-decision tables. For each recommenda-
tion, the guideline panel considered and agreed on the
following: the quality of the evidence, the balance of de-
sirable and undesirable consequences of compared
management options and the assumptions about the
values and preferences associated with the decision.
The guideline panel also explicitly took into account
possible extent of resource use associated with alterna-
tive management options. Recommendations and their
strength were decided by consensus and no recommenda-
tion required voting. The panel agreed on the final wording
of recommendations and remarks with further qualifica-
tions for each recommendation. The final document in-
cluding recommendations was reviewed and approved by
all members of the guideline panel.
We labelled the recommendations as either “strong” or
“conditional” according to the GRADE approach. We used
the words “the panel members recommend” for strong
recommendations and “suggest” for conditional recom-
mendations. Table 1 provides suggested interpretation of
strong and conditional recommendations by patients, cli-
nicians and health care policy makers.
Document review
A final draft document was reviewed by each member of
the guideline panel, finalized, approved, and submitted
to the WAO for peer review. The document was revised
to incorporate the pertinent comments suggested by the
external reviewers.
How to use these guidelines
The WAO GLAD-P guidelines about the use of probiotics
in the prevention of allergy in children are not intended to
impose a standard of care. They provide the basis for ra-
tional decisions. Clinicians, patients, third-party payers, in-
stitutional review committees, other stakeholders, or
the courts should never view these recommendations as
dictates. No recommendation can take into account all
of the often-compelling unique individual circum-
stances. Therefore, no one charged with evaluating
health care professional’s actions should attempt to
apply the recommendations from these guidelines by
rote or in a blanket fashion.
Statements about the underlying values and prefer-
ences as well as qualifying remarks accompanying each
recommendation are its integral parts and serve to facili-
tate more accurate interpretation. They should never be
omitted when quoting or translating recommendations
from these guidelines.
Recommendations
Question 1. Should probiotics vs. no probiotics be used
in pregnant women?
Summary of the evidence
We found eight systematic reviews [15-22] that ad-
dressed this question. The review by Foolad [20] and
Pelucchi [22] were the most recent and comprehensive.
However, as with the other six reviews, they considered
only the development of individual allergies as the main
outcomes. For instance, the reviews of Foolad, [20] Betsi,
[16] Doege, [17] Lee, [21] and Pelucchi [22] evaluated the
development of atopic dermatitis in infancy, whereas
Azad, [15] and Elazab [19] assessed the development of
asthma/wheezing. The review by Dugoua [18] focused on
the safety of probiotics administered during pregnancy.
Thus, we could not rely on the information from those re-
views alone.
We used the studies included in the systematic reviews
and we systematically searched for additional studies of
supplementation of probiotics in women during pregnancy.
We identified 21 randomized controlled trials (RCTs)
[23-43], of which only one [23] directly evaluated the use
of probiotics given to women during their pregnancy only
(direct evidence). In 4 of the remaining 20 studies
Table 1 Interpretation of strong and conditional recommendations
Implications for: Strong recommendation Conditional recommendation
Patients Most individuals in this situation would want the recommended
course of action, and only a small proportion would not.
The majority of individuals in this situation would want
the suggested course of action, but many would not.
Clinicians Most individuals should receive the intervention. Adherence to
this recommendation according to the guideline could be used
as a quality criterion or performance indicator. Formal decision
aids are not likely to be needed to help individuals make
decisions consistent with their values and preferences.
Recognize that different choices will be appropriate
for individual patients and that you must help each
patient arrive at a management decision consistent
with his or her values and preferences. Decision aids
may be useful in helping individuals to make decisions
consistent with their values and preferences.
Policy makers The recommendation can be adopted as policy
in most situations.
Policymaking will require substantial debate and involvement
of various stakeholders.
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probiotics were given to women during pregnancy and
subsequently during breastfeeding, [24,25,27,28] in 8 stud-
ies probiotics were used during pregnancy and then in in-
fants, [29-31,35-39] and in 8 studies probiotics were used
in all of these populations [26,32-34,40-43]. We extracted
data from the original publications and combined them in
meta-analysis, if appropriate. These studies include probio-
tics given as supplements and as part of functional food.
Owing to the heterogeneity of the interventions and limita-
tions in reporting of original studies it was not possible to
analyze the effects in each group separately. It was also not
possible to analyze the effects of individual probiotic spe-
cies and/or strains.
Follow-up in the studies ranged from 2 to 24 months
after childbirth. Confidence in the estimated effects of
probiotics on outcomes of interest was moderate to very
low owing to the risk of bias, indirectness of the evi-
dence and imprecision of the estimates (see evidence
profile for question 1 in the Additional file 2).
Fifteen studies measured and reported development of
eczema in the child [23-30,32,34,37-41]. The quality of
the evidence for this outcome was moderate owing to a
serious risk of bias. Although only one study [23] evalu-
ated the intervention given to women exclusively during
their pregnancy (direct evidence), we did not downgrade
the quality of the evidence for indirectness since the dir-
ect and indirect bodies of evidence were congruent. The
risk of eczema was reduced in children whose mothers
received a probiotic during pregnancy, compared to pla-
cebo (risk ratio [RR] 0.72, 95% confidence interval [CI]
0.61 to 0.85).
Development of asthma/wheezing in the child was re-
ported in 8 studies [23,24,29,35,36,40,42,43] and did not
differ between the probiotic and placebo arms (RR 0.93,
95% CI of 0.76 to 1.15). Available evidence from 3 stud-
ies [27,29,33] does not indicate that probiotics given to
pregnant women reduce the risk of developing food al-
lergy in the child. However, there were very few events
in these studies and thus the estimates are imprecise and
confidence interval does not exclude an appreciable
benefit or an appreciable harm (RR 1.49, 95% CI 0.58 to
3.81). Development of allergic rhinitis in the child was
assessed in 5 studies [24,29,33,35,42]. No effect of pro-
biotics on development of allergic rhinitis was observed
(RR 0.86, 95% CI 0.44 to 1.7). Three studies reported de-
velopment of “any allergy” [37,38,40]. No effect of pro-
biotics was observed (RR 0.93, 95% CI 0.8 to 1.08).
Adverse effects
Although poorly documented and defined, most com-
monly reported adverse events were mild and short-
term, i.e., vomiting, diarrhoea, rash, crying, and consti-
pation. They were explicitly described in three individual
studies [28,29,31] and no differences were detected
between the probiotic and the placebo arms (RR 1.14,
95% CI 0.91 to 1.42). However, the confidence in this es-
timate is low due to indirectness of the evidence and risk
of bias.
We found one health technology assessment (HTA)
that evaluated the risk of adverse effects of probiotics in
any population and age group [44]. It found 622 experi-
mental and observational studies that primarily exam-
ined supplementation of Lactobacillus alone or in
combination with other probiotics, often Bifidobacter-
ium. Interventions and adverse events were poorly docu-
mented in the individual studies. In 235 studies only
nonspecific safety statements were made (e.g. “well toler-
ated”). In this HTA, randomized trials failed to show an
increased risk of any adverse event associated with short-
term probiotic use (RR: 1.00, 95% CI: 0.93 to 1.07) as well
as gastrointestinal, infectious or other adverse events, in-
cluding serious adverse events (RR: 1.06, 95% CI: 0.97 to
1.16). However, the majority of studies included in this re-
port explicitly excluded pregnant and breastfeeding
women. Moreover, the long-term effects are unknown.
A small number of case reports described fungemia
and bacteremia potentially associated with the adminis-
tration of probiotics. Studies with a control group did
not measure such events routinely. RCTs that included
critically ill participants did not report an increased risk
of adverse events.
Desirable consequences
There is modest reduction of risk of developing eczema
in children with probiotic supplementation in pregnant
women (RR 0.72, 95% CI 0.61 to 0.85) when they are ad-
ministered during the pregnancy only and/or during
breastfeeding or to the infant.
Undesirable consequences
Adverse effects were not different between the probiotic
and placebo arms of the included studies. Based on the
evidence from studies in pregnant women and all studies
of probiotics included in the HTA report, panel mem-
bers judged the risk of adverse effects to be low. The
panel assumed that the burden of taking daily probiotic
supplement is limited.
Other considerations
We agreed that the values and preferences of women re-
garding the use of probiotics during pregnancy are likely
to depend on cultural and socioeconomic background.
Decision whether to use probiotics or not will also de-
pend on women’s prior experience and whether they
have already had children with allergy and the type of
that allergy. The panel noted that some women with dis-
orders of the immune system (e.g. autoimmune diseases)
might not accept potential risks.
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We explicitly considered the required resources. Prices
of probiotics are likely to vary substantially depending
on the setting, which may be a particularly important
consideration in low and middle-income countries. A
level and type of insurance may play a substantial role as
well. We noted that from the perspective of health sys-
tem probiotic supplementation in pregnancy might also
be cost effective given that probiotics would be used for
up to 9 months (in most studies probiotics were used
during the last 3 month of pregnancy which, if applied,
might also reduce the cost) and that the cost of treat-
ment of eczema usually extends over many years. In
some settings it may be prudent to consider equity as
the access to probiotics may depend on socioeconomic
status and coverage may depend on policymakers.
Conclusions and research needs
The guideline panel determined that there is a likely net
benefit from using probiotics in pregnant women. This
recommendation is based on trials investigating single
probiotics or mixtures of probiotics (See Additional
file 3). We have not found differences in the effects
among probiotics but that does not imply that such a
difference does not exist. Similarly, further research of
possible differences among the strains of the same spe-
cies might be warranted. There is a need for develop-
ment of instruments for evaluating the risk of allergy in
children, since the family history predicts only about
30% of the population risk. There is also some evidence
that first child is at higher risk for allergy than subse-
quent children. There is a need for rigorously designed
and executed randomized trials of probiotics in pregnant
women, especially those at higher risk for allergies in
their children, that properly measure and report patient-
important outcomes, including development of allergy,
quality of life and adverse effects. Long-term follow-up of
such studies to evaluate long-term effects is also needed.
We noted the following additional research questions:
1) is the effect of natural probiotics in food different from
that of supplementation and 2) is there an added benefit
from probiotic supplementation in addition to natural
probiotics? Future research, if done, may have an import-
ant impact on this recommendation.
What others are saying
The European Academy of Allergy and Clinical Immun-
ology (EAACI) Food Allergy and Anaphylaxis Guidelines
state that “there is no evidence to recommend that women
modify their diet during pregnancy or take any supple-
ments such as probiotics in order to prevent food allergy
in their children [45]”.
Guidelines from the US National Institute of Allergy
and Infectious Diseases, [9] the European Society for
Paediatric Gastroenterology, Hepatology, and Nutrition
(ESPHGAN), [46] the World Gastroenterology Organ-
isation Global Guidelines on Probiotics and Prebiotics
[47], and the Food & Agriculture Organization (FAO)/
World Health Organization (WHO) Guidelines on Pro-
biotics [48] make no specific recommendations about
the use of probiotics in pregnant women.
Recommendation 1
The WAO guideline panel suggests using probiotics in
pregnant women at high risk for allergy in their chil-
dren, because considering all critical outcomes,
there is a net benefit resulting primarily from pre-
vention of eczema (conditional recommendation, very
low quality evidence).
Values and preferences
This recommendation places a relatively high value on
prevention of eczema in children, and a relatively lower
value on avoiding possible adverse effects.
Explanations and other considerations
There is lack of evidence that probiotics prevent any other
allergy. In most studies probiotics were used in the last 3
months of pregnancy. This recommendation applies to
otherwise healthy women and cannot be generalized to
those with compromised immune system function. High
risk for allergy in a child is defined as biological parent or
sibling with existing or history of allergic rhinitis, asthma,
eczema, or food allergy.
Question 2. Should probiotics vs. no probiotics be
used in breastfeeding mothers?
Summary of the evidence
None of the systematic reviews that we identified dir-
ectly evaluated using probiotics in breastfeeding mothers
for the prevention of allergy in their children. Therefore,
we performed a systematic review of randomized con-
trolled trials of probiotics in breastfeeding mothers.
We found 13 RCTs that investigated the use of probio-
tics in breastfeeding mothers, [24-28,32-34,40-43,49] al-
though only one evaluated probiotic supplementation
exclusively during the breastfeeding period [49]. In the
other 12 studies probiotics have also been given during
pregnancy or to the infants. Follow-up in the studies ranged
from 2 to 24 months after childbirth. Confidence in the es-
timated effects of probiotics on most outcomes of interest
was very low owing to the risk of bias, indirectness of the
evidence and imprecision of the estimates (see evidence
profile for question 2 in the online Additional file 2).
Ten studies investigated the effect of probiotics given
to breastfeeding mothers on development of eczema in
infants [24-28,32,34,40,41,49]. Only one study [49] eval-
uated the intervention given to women exclusively dur-
ing the breastfeeding period (direct evidence). However,
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we did not downgrade the quality of the evidence for in-
directness since the direct and indirect bodies of evi-
dence were congruent. The use of probiotics during the
breastfeeding period reduced the rate of eczema in in-
fants when compared to placebo (RR 0.61, 95% CI from
0.50 to 0.64). Asthma/wheezing was measured in 4 stud-
ies [24,40,42,43] in which the intervention was adminis-
tered not only during the breastfeeding period but also
during pregnancy and/or to the infant). No difference
was observed between the probiotic and placebo arms
but there were relatively few events and the confidence
interval does not exclude an appreciable benefit or an
appreciable harm (RR of 1.05, 95% CI from 0.59 to 1.87).
Two studies assessed the risk of developing food allergy
[27,33]. No difference was observed with probiotic sup-
plementation (RR 1.7, 95% CI 0.58 to 4.96) but the con-
fidence interval does not exclude an appreciable harm or
an appreciable benefit. Three trials assessed develop-
ment of allergic rhinitis [24,33,42]. Again, there were
relatively few events and the results are very imprecise
(RR 0.86, 95% CI 0.21 to 3.47. Two studies reported the
risk of developing “any allergy” [40,49] and failed to
show a benefit or harm from probiotic supplementation
to breastfeeding mothers (RR 1.02, 95% CI 0.71 to 1.46).
Adverse events
Adverse events were reported inconsistently. One ran-
domized trial [28] with a mean follow-up of 24 months
provided indirect and imprecise evidence of no differ-
ence between the probiotic and placebo arms (RR 1.52,
95% CI from 0.79 to 2.96). The aforementioned HTA re-
port provided very low quality evidence about safety of
probiotics in various populations and age groups [44].
However, the majority of studies included in this report
explicitly excluded pregnant and breastfeeding women.
Desirable consequences
Probiotic supplementation to breastfeeding mothers re-
duced the risk of developing eczema in children (RR 0.61,
95% CI from 0.50 to 0.64). However, there is some con-
cern about the directness of this evidence as in most stud-
ies probiotics were given not only during the breastfeeding
period but also during pregnancy and/or to infants.
Undesirable consequences
Any estimate of potential adverse effects is very uncer-
tain due to small number of patients and inadequate
reporting. However, based on the evidence from all stud-
ies of probiotics, panel members judged the risk of ad-
verse effects to be low. The panel assumed that the
burden of taking daily probiotic supplement is limited.
Other considerations
We agreed that the considerations of values and prefer-
ences, resource implications and equity are likely similar
to those in pregnant women. We also noted that the
cost of probiotics is much lower than cost of a formula
which may have an impact on the assessment of oppor-
tunity cost.
Conclusions and research needs
The guideline panel determined that there is a likely net
benefit from using probiotics in breastfeeding women. It
is likely that probiotic supplementation in breastfeeding
mothers reduces the risk of eczema in children. There is
very low certainty that there is any effect of probiotic
use by breastfeeding mothers on the development of
other allergies in their children. We noted that, albeit
possibly owing to chance, the relative magnitude of both
benefits and downsides seems higher when probiotics
were used by breastfeeding mothers compared to using
them in pregnant women (see Additional file 2 – evi-
dence profiles for questions 1 and 2).
We have not found differences in the effects among
probiotics but that does not imply that such a difference
does not exist. Similarly, further research of possible dif-
ferences among the strains of the same species might be
warranted. There is a need for rigorously designed and
well-executed randomized trials of probiotics in breast-
feeding women that would properly measure and report
patient-important outcomes, including quality of life and
adverse effects. Long-term follow-up of such studies to
evaluate long-term effects is also needed. We noted the
following additional research questions: 1) is the effect
of natural probiotics in food different from that of sup-
plementation and 2) is there an added benefit from pro-
biotic supplementation in addition to natural probiotics?
Future research, if done, may have an important impact
on this recommendation.
What others are saying
The EAACI Food Allergy and Anaphylaxis Guidelines
state “there is no evidence to recommend that breast-
feeding women should modify their diet or take any sup-
plements such as probiotics in order to prevent food
allergy in their children”. [45]. No other guideline that
we reviewed made a specific recommendation about the
use of probiotics in breastfeeding mothers [47,48].
Recommendation 2
The WAO guideline panel suggests using probiotics in
women who breastfeed infants at high risk of develop-
ing allergy, because considering all critical outcomes,
there is a net benefit resulting primarily from preven-
tion of eczema (conditional recommendation, very low
quality evidence).
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Values and preferences
This recommendation places a relatively high value on
prevention of development of eczema, and relatively
lower value on avoiding possible adverse effects.
Explanations and other considerations
There is lack of evidence that probiotics prevent any
other allergy. This recommendation applies to otherwise
healthy women and caution should be applied in general-
izing to women with compromised immune system func-
tion. High risk for allergy in a child is defined as biological
parent or sibling with existing or history of allergic rhin-
itis, asthma, eczema, or food allergy.
Question 3. Should probiotics vs. no probiotics be
used in healthy infants?
Summary of the evidence
We found 5 systematic reviews that assessed the use of
probiotics in infants [15,19,50-52]. Most concentrated
only on the evaluation of development of eczema (atopic
dermatitis). Therefore, we performed a systematic review
and we found 23 RCTs [26,29-43,53-59] in which pro-
biotics were used in infants. Of these, 7 studies investi-
gated the use of probiotics in infants only, [53-59] 8
studies assessed the use of probiotics in infants and in
women during pregnancy, [29-31,35-39] and another 8
studies assessed the effect of probiotics given to preg-
nant women and subsequently breastfeeding mothers
and infants [26,32-34,40-43]. We extracted data from
the original publications and combined them in meta-
analysis, if appropriate.
Follow-up in the included studies ranged from 4 to 36
months. The confidence in the estimated effects of probio-
tics on outcomes of interest was low to very low owing to
the risk of bias, indirectness of the evidence and impreci-
sion of the estimates. The only outcome for which the
available evidence provides moderate confidence in the ef-
fect of probiotics is development of eczema (see evidence
profile for question 3 in the Additional file 2).
Fifteen randomized trials measured development of
eczema [26,29,30,32,34,37-41,54,55,57-59] Only 5 of the
10 studies provided direct evidence (i.e., evaluated the ad-
ministration of probiotics only to infants); we did not
downgrade the quality of the evidence because of indirect-
ness since the direct and indirect bodies of evidence were
congruent. Probiotics, when given to infants, decreased
the risk of developing eczema compared to placebo (RR
0.81, 95% CI 0.70 to 0.94). Nine studies assessed develop-
ment of asthma/wheezing 29,35,36,40,42,43,54,56,59]. No
difference between the probiotic and placebo groups was
observed (RR 0.98, 95% CI from 0.78 to 1.23). Only 3 of
the 9 studies provided direct evidence but the direct and
indirect bodies of evidence were congruent. Development
of food allergy was measured in 5 trials [29,33,54-56] and
no difference between the probiotics and placebo arms
was noted (RR 0.9, 95% CI from 0.57 to 1.41). Four trials
assessed development of allergic rhinitis [29,33,35,42].
These studies failed to demonstrate an effect of probiotics
on development of allergic rhinitis in children (RR 0.83,
95% CI from 0.39 to 1.79). However, there was serious in-
consistency in the results of the studies that we could not
explain either by the risk of bias or by type of probiotic
used or the population that received probiotics (pregnant
women, breastfeeding mothers and/or infants). Four ran-
domized trials [37,38,40,56] reported development of “any
allergy”. No differences were detected between probiotic
and placebo arms (RR 0.97, 95% CI from 0.85 to 1.12).
Adverse effects
Only 4 studies reported adverse events [29,31,53,55]. No
differences were detected between the probiotic and pla-
cebo arms (RR 1.1, 95% CI 0.64 to 1.91). Two systematic
reviews assessed the rate of adverse events from random-
ized trials and observational studies [50,51] showing similar
results. The overview of systematic reviews by Foisy et al.
[50] states that the only significant parent-reported event
was more spitting up in their infants at one and two
months of age (RR 1.88, 95% CI from 1.03 to 3.45; and RR
1.69, 95% CI from 1.02 to 2.80 respectively). The system-
atic review by Mugambi et al. [51] reported no significant
effect of adding probiotics to infant formula on any adverse
effects, including spitting up/regurgitation, gastrointestinal
complaints, and diarrhoea. However, all estimates were im-
precise owing to relatively low number of events.
Nutrition status
Three studies [31,53,58] assessed the nutrition status in
infants, whether by measuring their body mass index,
weight at the end of the follow-up, or change in weight.
No difference was detected between intervention and
control arms (standardized mean difference: 0.02 lower,
95% CI from 0.17 lower to 0.12 higher). One systematic
review of probiotics added to infant formula investigated
its impact on nutritional status and failed to find a dif-
ference between probiotic and placebo [51].
Desirable consequences
Probiotic supplementation in infants is likely to reduce
the risk of developing eczema.
Undesirable consequences
Any estimate of potential adverse effects was graded as
low certainty due to inadequate reporting in primary stud-
ies. However, given the available evidence, the guideline
panel considered the risk of adverse effects most likely to
be low. Panel members noted that certain preparations of
probiotics might not be acceptable to some children be-
cause of unpleasant taste.
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Other considerations
If probiotics are used in infants, it is not clear when they
should be started and how long they should be used.
Also there is uncertainty about the dosage and whether
the effectiveness differs for single probiotic strains com-
pared with mixtures of several strains and/or species.
These considerations concern otherwise healthy infants
in whom probiotics would be used for prevention of allergy.
It does not concern using probiotics for specific indications
in infants with specific medical condition, e.g. for reducing
the risk of antibiotic-induced diarrhea or prevention of nec-
rotizing enterocolitis in premature infants [50].
Conclusions and research needs
The guideline panel determined that there is a likely net
benefit from using probiotics in infants. It is likely that
probiotic supplementation in infants reduces the risk of
developing eczema. There is very low certainty that
there is any effect of probiotics on other outcomes. We
have not found differences in the effects among probio-
tics but that does not imply that such a difference does
not exist.
There is a need for rigorously designed and well exe-
cuted randomized trials of probiotics in infants that
would measure and adequately report patient-important
outcomes, including adverse effects. Similarly, further re-
search of possible differences among the strains of the
same species might be warranted. We noted the following
additional research questions: 1) is the effect of natural
probiotics in food different from that of supplementation
and 2) is there an added benefit from probiotic supple-
mentation in addition to natural probiotics? Future re-
search, if done, may have an important impact on this
recommendation.
What others are saying
The EAACI Food Allergy and Anaphylaxis Guidelines
state that “there is no evidence to recommend prebiotics
or probiotics or other dietary supplements based on par-
ticular nutrients to prevent food allergy”. [45] The
World Gastroenterology Organization Global Guidelines
establish that “the strongest evidence is for the preven-
tion of atopic dermatitis when certain probiotics are ad-
ministered to pregnant mothers and newborns up to 6
months of age [47]”. The FAO/WHO guidelines do not
give specific recommendations about the use of probio-
tics in infants [48].
Recommendation 3
The WAO guideline panel suggests using probiotics in
infants at high risk of developing allergies, because
considering all critical outcomes, there is a net benefit
resulting primarily from prevention of eczema (condi-
tional recommendation, very low quality evidence).
Values and preferences
This recommendation places a relatively high value on
prevention of eczema, and relatively lower value on
avoiding possible adverse effects.
Explanations and other considerations
There is lack of evidence that probiotics prevent any
other allergy. This recommendation applies to otherwise
healthy infants with the goal of preventing allergies. It
does not apply to the use of probiotics for other indica-
tions, e.g. prevention of antibiotic-associated diarrhea or
enterocolitis in premature infants.
Priorities for revision of the guidelines
Plans for updating these guidelines
Guidelines are living documents. To remain useful, they
need to be updated regularly as new information accumu-
lates. A revision of this document will be needed, because
there was limited evidence for many clinical questions.
This document will be updated when major new research
is published. The need for update will be determined not
later than in 2018.
Updating or adapting recommendations locally
The methods used to develop these guidelines are trans-
parent. The recommendations have been developed to
be as specific and detailed as possible without losing
sight of the simplicity of the document. Since GLAD-P
are meant as international guidelines, the guideline panel
encourages feedback on its all aspects including their ap-
plicability in individual countries. This feedback will be
considered when revising the document.
Adaptation of these guidelines will be necessary in
many circumstances. Depending on when such a process
takes place, the following steps should be taken:
◾ Appointing a guideline committee comprising
clinicians and methodologists
◾ Determining the scope of the localized guidelines
◾ Defining the clinical questions to be addressed
◾ Updating the evidence profiles and evidence-to-
decision tables, if necessary
◾ Reviewing the recommendations in the GLAD-P
guidelines (the recommendations may need to be modi-
fied at a local level, depending on the local values and
preferences, availability of medications, costs, etc.)
◾ Disseminating the guidelines, with a clear “use by” date
◾ Developing a method to obtain feedback and plans
for review and update.
Priorities for research
During the guideline development process we identified a
need for more data on specific topics. This results in the
following recommendations for research. We summarize
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these gaps in the evidence as research recommendations,
to assist those in a position to provide such information
by the design and execution of specific research projects.
Specific research needs to be addressed:
1. Development of instruments for evaluating the risk
of allergy in children (the family history predicts
only about 30% of the population risk).
2. Evaluation of effects of using probiotics in formulas.
3. Evaluation of effects of using probiotics in
breastfeeding mothers specifically in that period
(as opposed to intervention administered also during
pregnancy and to children).
4. Evaluation of the effects of different ways of
administration of probiotics , e.g. as milk or dairy
supplements, stand-alone supplements, etc.
5. Performance of rigorously designed, adequately
powered, and well executed randomized trials of
probiotics in infants who did not receive probiotics
prenatally and/or during breastfeeding; studies
should include infants considered to be at high and
low/average risk for allergies and should properly
report patient-important outcomes, including
adverse effects. The estimated optimal information
size for this question is from approximately 2500
participants (for eczema) to 27,000 participants (for
food allergy). However, for the evaluation of adverse
effects a large compilation of RCTs as well as
observational studies might be necessary with
possible thousands of observations.
6. Evaluation which of the 3 populations (pregnant
women, breastfeeding mothers and infants) should
receive probiotics – whether there is a larger
benefit with supplementation in one or
combination of these populations and, if so, which
populations to target.
7. Evaluation whether any effect of probiotics is a class
effect or differs among species and strains of
microorganisms. An effect of shelf life on
effectiveness of probiotics also warrants further
investigation [60].
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